Dissection of Staphylococcus Aureus Infection From Colonization in Cystic Fibrosis Patients (StaphCI)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Mukoviszidose eV Bonn Germany
Information provided by:
University Hospital Muenster
ClinicalTrials.gov Identifier:
NCT00669760
First received: April 28, 2008
Last updated: August 3, 2011
Last verified: August 2011

April 28, 2008
August 3, 2011
July 2008
September 2011   (final data collection date for primary outcome measure)
bacterial load of sputum cultures [high (>/= 1000000CFU/ml); low (<1000000CFU/ml)] [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00669760 on ClinicalTrials.gov Archive Site
antibody titres against S. aureus specific antigens; S100A12, IL-8, TNF-alpha, CRP [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Same as current
 
 
 
Dissection of Staphylococcus Aureus Infection From Colonization in Cystic Fibrosis Patients
Dissection of Staphylococcus Aureus Infection From Colonization in Cystic Fibrosis Patients, a Non-interventional, Prospective, Longitudinal Multicenter Study.

Staphylococcus aureus is not only one of the first pathogens infecting the airways of cystic fibrosis (CF) patients, but also a highly prevalent microorganism (>60% of all CF patients; European and American CF registries; (4,25), which often persists for several years in the respiratory tract of CF patients.

The purpose of this study is to dissect infection by S. aureus from colonization. Therefore, the following non-interventional prospective, longitudinal multicenter study will be conducted to develop the following hypothesis:

CF patients with high bacterial loads are more likely to be infected by S. aureus than patients with low bacterial loads.

Primary endpoint: bacterial load of sputum cultures

Secondary endpoints:

  • nasal carriage
  • molecular analysis of S. aureus (Monoclonal/polyclonal)
  • serum: S. aureus-specific antibodies, S100A12, IL-8, TNF-alpha
  • sputum: S100A12, IL-8, myeloperoxidase
  • S. aureus therapy regimens
  • lung function tests: FEV1, deltaFVC , deltaMEF25
  • BMI development

Inclusion criteria: S. aureus cultures for more than 6 months within the last year, children (>6 years) and patients, who are able to perform lung function tests Exclusion criteria: P. aeruginosa and/or B. cepacia cultures from the specimens for more than 6 months within the last year before recruitment or during the study period In addition to microbiological investigations and clinical laboratory tests, the actual clinical situation will be evaluated and reported during the study period. The results of this observational study will be used to carefully plan a clinical interventional study. Furthermore, with the results it might be possible to characterize a subpopulation of patients, which is at greater risk for S. aureus infections.

Protocol synopsis Title: Dissection of Staphylococcus aureus infection from colonization in cystic fibrosis patients. A non-interventional prospective, 2-year longitudinal multicenter study

Study objectives: The aim of the study is to dissect S. aureus infection from colonization of the pathogen in airway secretions of CF patients during a 2 year period by means of a non-interventional, prospective, longitudinal multicenter study.

The following hypothesis will be developed:

CF patients with high bacterial loads are more likely to be infected by S. aureus than patients with low bacterial loads.

Definition of infection:

  • change in volume, colour or consistency of sputum (exacerbation)
  • increased cough
  • malaise, fatigue or lethargy
  • body temperature more than 38°C
  • new or increased hemoptysis
  • anorexia or weight loss
  • sinus pain or tenderness
  • change in sinus discharge
  • change in chest sounds
  • ten percent decrease in pulmonary function from a previous recorded value (FEV1, MEF25)
  • radiographic changes indicative of pulmonary infection

Primary endpoint: bacterial load of sputum cultures [high (>/= 106CFU/ml); low (<106CFU/ml)]

Secondary endpoints are:

  • assessment of nasal S. aureus carriage
  • serum samples: antibody titres against S. aureus specific antigens; S100A12, IL-8,TNF-alpha, CRP
  • molecular analysis of S. aureus colonization/infection (monoclonal or heteroclonal)
  • sputa analysis: activity of S100A12, IL-8 and myeloperoxidase
  • antibiotic treatment regimens against S. aureus
  • body mass index
  • lung function tests: FEV1, deltaFVC, deltaMEF25

Extensive microbiological investigations will be performed when the patients are seen at their regular visits in the outpatient clinics or if exacerbations occur. During the study period of 2 years, at least 8 visits to the outpatient clinic should be recorded. The following clinical parameters will be documented:

  • lung function
  • body mass index (weight/height)
  • antibiotic treatment Diagnosis: CF and positive S. aureus cultures for more than 6 months within the last year Localisation of the study: multicenter study in Germany Number of centers: Seven centres agreed already to participate in the study. More centers have been and will be contacted.

Design: non-interventional prospective, longitudinal multicenter study Planned number of patients/volunteers: 228 Inclusion criteria: positive S. aureus cultures for more than 6 months within the last year; children (>6 years) and patients with CF, who are able to perform lung function tests Exclusion criteria: Pseudomonas aeruginosa and/or Burkholderia cepacia colonization or infection for more than 6 months within the last year before recruitment; patients who have not been colonized with these pathogens before but acquire them within the study period and are colonized/infected for more than 6 months during the observation period

Observational
Observational Model: Case-Only
Time Perspective: Prospective
Retention:   None Retained
Description:

Sera

Probability Sample

CF-patients with persistent S. aureus culture in their airway specimens

Cystic Fibrosis
Other: non-interventional study
does not apply
Other Name: does not apply
Observation
CF-patients with persistent culture of Staphylococcus aureus in their respiratory specimens
Intervention: Other: non-interventional study
 

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
193
December 2011
September 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • positive S. aureus cultures for more than 6 months within the last year; children (>6 years) and patients with CF, who are able to perform lung function tests

Exclusion Criteria:

  • Pseudomonas aeruginosa and/or Burkholderia cepacia colonization or infection for more than 6 months within the last year before recruitment; patients who have not been colonized with these pathogens before but acquire them within the study period and are colonized/infected for more than 6 months during the observation period
Both
6 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Austria,   Germany
 
NCT00669760
Muko e.V. S05/07
No
Dr. Barbara C. Kahl, Dept. of Med. Microbiology, University Clinics Muenster, Germany
University Hospital Muenster
Mukoviszidose eV Bonn Germany
Principal Investigator: Barbara C Kahl, MD Dept. Med. Microbiology, University Clinics Muenster, Germany
University Hospital Muenster
August 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP